Background: COPD is characterized by a multi-component character involving a state of lowgrade systemic inflammation and an increased prevalence of cardiovascular co-morbidity. The role of circulating leptin and other adipokines in the involvement of the systemic inflammation in COPD is only studied scarcely. Objective: To investigate gender related differences in the adipokine metabolism in relation to systemic inflammatory biomarkers in clinically stable subjects with COPD. Methods: In total, 91 clinically stable COPD patients and 35 healthy control subjects, matched for body mass index (BMI) with the COPD subjects, were included. Lung function measurement and body composition were performed in patients with COPD. In the total group, plasma concentration of the adipokines (leptin, adiponectin and resistin) and systemic inflammatory biomarkers C-reactive protein (CRP), interleukin 6 (IL-6), tumor necrosis factor a (TNFa), and its soluble receptors 55 and 75 (sTNFa-R55, R75) were analyzed. (M.-K. Breyer). e On behalf of the CIRO Network. For more details see Appendix section. a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / r m e d Respiratory Medicine (2011) 105, 1046e1053 0954-6111/$ -see front matter ª
Introduction
Chronic obstructive pulmonary disease (COPD), a disease characterized by partially reversible airflow limitation, is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases. 1 Furthermore, COPD is these days recognized as a multi-component disease, involving various extra-pulmonary manifestations like low-grade systemic inflammation and an increased prevalence of cardiovascular comorbidity. 2 Worldwide attention has been focused on COPD, as COPD is predicted to become the third leading cause of death worldwide by the year 2020 [1] . Since recent years, the prevalence of COPD in women has been increasing, and the question arises if the nature of the biologic injury differs between COPD men and women. 3 Various gender differences are recognized in COPD, as women exhibit anatomically smaller airway lumens and they suffer from less extensive emphysema. 4 In addition, women with COPD experience more symptoms of depression compared to male, 5 and clinical data suggest sex hormones affecting airway function. 6 Gender related differences in the extra-pulmonary manifestation of COPD are barely investigated. Interestingly, a recent study showed that systemic effects of smoking differ between men and women. 7 The authors demonstrated decreased plasma concentrations of the antiinflammatory adipokine adiponectin in women. In addition, the same authors reported increased plasma levels of high sensitive C-reactive protein (CRP) in men. 7 These differences may contribute to a different etiology of extrapulmonary manifestations of COPD among men and women.
Circulating leptin is originally described as an adipocytederived hormone involved in the processes of limiting food intake, increasing energy expenditure and decreasing metabolic efficiency by activating its functional receptor (Ob-Rb) in the hypothalamus. 8 Hereby, leptin is positively linked with body mass index (BMI; weight in kilograms divided by squared height in meters) and fat mass. The structure of leptin and its receptor classify leptin as a type I cytokine, increasing acutely by inflammatory and infectious stimuli, such as tumor necrosis factor (TNF)a and lipopolysaccharide 9 In general, circulating leptin levels have been shown to be positively related to cardiovascular disease 10, 11 and in addition are gender related and higher in healthy women compared to healthy men, independent of BMI. Indeed, for the same amount of fat mass, women have higher circulating leptin levels compared to men. 12 The role of circulating leptin and other adipokines in the involvement of the systemic inflammation in COPD is only studied scarcely and mainly in male COPD patients with a low BMI (<21 kg/m 2 ). 13e16 From these studies, it is concluded that circulating leptin plays a physiological role in COPD, even in underweight patients.
The present study primarily aimed to unravel gender related differences in the adipokine metabolism in clinically stable subjects with COPD. Secondarily, we aimed to compare plasma levels of adipokines (leptin, adiponectin and resistin) with systemic inflammatory biomarkers, such as CRP, interleukin 6 (IL-6), tumor necrosis factor a (TNFa), and its soluble receptors 55 and 75 (sTNFa-R55, R75) in COPD and in healthy control subjects.
Materials and methods

Study population
Data were collected from 91 subjects with COPD, stratified in 4 groups by BMI and matched for age, gender and disease severity. All patients were entering pulmonary rehabilitation at the Centre of expertise for chronic organ failure (Ciro), Horn, the Netherlands. Patients were excluded, if they had an exacerbation within the last 4 weeks before study entry. All patients were free of taking oral corticosteroids or antibiotics. Other current medication use was recorded, particularly the use of inhaled corticosteroids, and any anti-inflammatory medication, particularly NSAR, and statins. The control group is composed of 35 Caucasian non-diabetic genetically independent subjects. They were extracted from the spouses databank of Familial Combined Hyperlipidemia families. The study protocol has been described in detail elsewhere. 17 Any lipid-lowering medication had been withdrawn during the last 2 weeks before blood sampling. The healthy subjects were age and BMI matched with the COPD patients. The Medical Ethical Committee of the University Hospital Maastricht approved the study, and all subjects gave written informed consent.
Lung function, arterial blood gases and body composition in the subjects with COPD
In all patients, lung function parameters were collected using standardized spirometry (Masterlab, Viasys, Germany). The degree of severity of airflow limitation was classified according to the GOLD guidelines (GOLD stage 1: FEV 1 /FVC < 70% and FEV 1 > 80% of the predicted values; GOLD stage 2: FEV 1 /FVC < 70% and FEV 1 between 80 and 50% of the predicted values; GOLD stage 3: FEV 1 /FVC < 70% and FEV 1 between 50 and 30% of the predicted values; and GOLD stage 4: FEV 1 /FVC < 70% and FEV 1 < 30% of the predicted values or FEV 1 < 50% of the predicted values plus chronic respiratory failure). 1 Arterial oxygen tension (PaO 2 ) and arterial carbon dioxide tension (PaCO 2 ) were measured while patients were breathing room air or when on long term oxygen therapy (LTOT; n Z 4) when breathing oxygen and have been analyzed with a blood gas analyzer (ABL 700, Radiometer, Copenhagen, Denmark).
Body height was measured to the nearest 0.1 cm. Body weight was assessed by using an electronic beam scale with digital readout to the nearest 0.1 kg after emptying the bladder and with the subjects standing barefoot and wearing light indoor clothing. BMI was calculated as body weight/height 2 (kg/m 2 ). A priori, BMI was categorized into low (<21 kg/m 2 ), normal (21e24.9 kg/m 2 ), high (25e29.9 kg/m 2 ) and obese (30 kg/m 2 ). Body composition (fat free mass, FFM, and fat mass, FM) has been assessed using an overnight-fasting bioelectrical impedance analysis (Bodystat Ò ). FFM was calculated by using disease and gender-specific equations. 18 FFM index (FFMI) was calculated as FFM in kilogram divided by squared height in meters. FFM depletion was defined as FFMI 15 (females) and 16 (males) kg/m 2 . 18 FM in kilogram was calculated as total body weight minus FFM. Additionally, patients' smoking status (never, former, current smoker), amount of packs smoked per year (PY) and patients' co-morbidities were recorded.
Blood sample analyses
Blood sampling occurred after overnight fast. In all participants blood samples were analyzed with the same, most recent available kits. HsCRP was assessed in duplicate by high-sensitivity particle-enhanced immunoassay (COBAS Micra, Radiometer, Copenhagen, Denmark). IL-6 was determined with the PeliKine CompactTM human IL-6 ELISA kit (Sanquin Reagents, Amsterdam, the Netherlands). Circulating leptin, adiponectin and resistin were assessed using a human leptin ELISA, a human high-sensitivity adiponectin ELISA and a human resistin ELISA, respectively (BioVendor, Brno, Czech Republic). TNFa was determined using Qauntikine HS-human TNFa/NTFSF1A immunoassay (R&D, Minneapolis, USA). ELISA kits for detection of the sTNFa-R55 and sTNFa-R75 were purchased from HyCult Biotechnology (Uden, the Netherlands). Detection limits of the single assays were: 0.23 mg/l for hsCRP; 0.2 pg/ml for IL-6; 1.5 ng/ml for leptin; 5 ng/ml for adiponectin; 1 mg/ml for resistin; 0.5 pg/ml for TNFa; 16 pg/ml for both sTNFa-R55 and sTNFa-R75. Only in 2 healthy control subjects, levels of circulating leptin were below the defined lower level of detection.
Statistical analyses
All analyses were performed using Statistical Package for the Social Sciences (SPSS) version 15.01. for Windows. Metabolic data of the COPD subjects were stratified for BMI. Categorical variables have been described as frequencies, while continuous variables are presented as median and 25th to 75th percentile, due to their skewed distribution. Evaluation of differences in continuous variables between two groups was done using the non-parametric ManneWhitney U test, while differences between more than two groups were tested using the KruskaleWallis test. Categorical variables were tested using the chi 2 -test. In addition, due to the high degree of correlation between circulating leptin and total body fat mass (r Z 0.79; p < 0.01), leptin to fat mass ratio (leptin/FM) was created. The interaction between BMI and gender on leptin/FM was tested by general linear model. The Bonferroni correction was performed to correct for multiple comparison. Spearman correlation coefficient was calculated to test correlations between adipokines and biomarkers for systemic inflammation in the COPD group. A p-value of 0.05 was considered significant.
Results
On average, subjects with COPD had moderate to severe COPD, a normal BMI, FFMI and normal arterial blood gases ( Table 1 ). In total, 80% of COPD patients inhaled corticosteroids and 40% were using any anti-inflammatory medication. After stratification for gender, both men and women with COPD showed normal BMI and arterial blood gases. Age, FMI, FFMI, and the amount of PY were significantly different between male and female COPD patients.
No differences were found in use of inhaled corticosteroids or anti-inflammatory medication, after stratification for gender. When comparing subjects with COPD to healthy age [median age: 60.0years (53.3e65.8, 25the75th percentile), sex (67% male)], and BMI matched subjects [median BMI: 26.6 kg/m 2 (23.1e29.5, 25the75th percentile)] significantly higher levels of CRP, IL-6, and circulating leptin were found in the COPD group (Table 2 ). After stratification for gender, men with COPD had higher levels of CRP and IL-6 compared to their healthy peers. Women with COPD had higher levels of circulating leptin compared to their healthy peers. When comparing men and women, men with COPD had lower circulating levels of adiponectin and leptin and lower leptin/FM compared to their female counterparts. Within the healthy subjects, men showed lower levels of adiponectin compared to women. There were no differences in plasma concentration of TNFa, its soluble receptors R55 and R75, and resistin between the groups. Table 3 shows age, lung function parameters, pack years, and plasma concentration of systemic inflammatory biomarkers and adipokines in subjects with COPD after stratification for gender and BMI. Age, the degree of lung function impairment, the amount of PY, and the use of inhaled corticosteroids and any anti-inflammatory medication were not different between the BMI strata, neither in male nor in female. After correcting for these potential confounders, there was a significant increase in CRP levels toward higher BMI strata in women, and increased leptin levels toward higher BMI strata for both men and women. There was no difference in the levels of other systemic inflammatory biomarkers and plasma adiponectin and resistin levels among BMI strata. Leptin/FM for different BMI categories and gender in COPD is shown in Fig. 1 . In both men and women, leptin/FM increased with increasing BMI, and there was a significant interaction between gender and BMI to a higher increase in the women with COPD (p < 0.01).
When COPD subjects were stratified for gender, no significant Spearman's correlation coefficient was found between plasma leptin and adiponectin concentration and plasma CRP (p Z 0.721, p Z 0.647), IL-6 (p Z 0.745, p Z 0.621), TNFa (p Z 0.332, p Z 0.449) and its soluble receptors 55 (p Z 0.989, p Z 0.297) and 75 (p Z 0.514, p Z 0.860) for men. For women, plasma leptin concentration was significantly correlated with plasma CRP concentration (r Z 0.40, p < 0.01). For both men and women, plasma resistin concentration was significantly correlated with CRP (r Z 0.23, p < 0.05), IL-6 (r Z 0.41, p < 0.01), sTNFa-R55 (r Z 0.44, p < 0.01), and sTNFa-R75 (r Z 0.38, p < 0.01).
Discussion
The present study is the first that evaluated various adipokines, such as leptin, adiponectin and resistin and biomarkers of systemic inflammation in men and women with COPD compared to healthy subjects and after strati-fication for BMI. Subjects with COPD were characterized by systemic inflammation which was reflected in increased levels of CRP and IL-6. TNFa, its soluble receptors R55 and R75, circulating levels of adiponectin and resistin were not different between the COPD and the healthy subjects. In women with COPD, leptin concentration was increased when compared to men with COPD as well as when compared to healthy women. Moreover, leptin secretion increased with increasing fat mass to a greater extent in COPD women compared to their male counterparts, con-firming our hypothesis of a gender-specific leptin metabo-lism in COPD. It is well recognized that even clinically stable subjects with COPD are characterized by low-grade systemic inflammation. This is reflected by an increase of various inflammatory biomarkers, such as CRP, TNFa, its soluble receptors, IL-8, lipopolysaccharide binding protein (LBP), and fibrinogen. 19 However, to date no 'sentinel biomarker' indicating (low-grade) systemic inflammation in COPD exists. In the present study, the systemic low-grade inflammation in COPD was reflected by increased levels of CRP and IL-6, whereas plasma levels of TNFa and its soluble receptors were not different between the COPD group and the healthy subjects. Furthermore, within the COPD group, the CRP concentration increased with increasing BMI, while this trend was not seen for the other systemic inflammatory biomarkers. Comparison of studies concerning systemic inflammation in patients with COPD with different nutri-tional status is challenging as no consistent definition for the nutritional status is used among these studies. In the present study, subjects with COPD were clinically stable and stratification for nutritional status was based on BMI. The finding of constant TNFa levels between the groups can imply a contribution of TNFa in weight losing or muscle wasting patients, but not in weight stable patients. This assumption is strengthened by a recent paper which demonstrated increased plasma levels of CRP and IL-18 but constant levels of TNFa in patients with COPD compared to BMI matched healthy subjects. 20 Plasma CRP concentration on the other hand, has been consistently related to increased BMI and FM, suggesting a pivotal role of CRP in leptin/fat mass ratio Women Men * * * Fig. 1 Leptin/fat mass for different BMI categories and gender in COPD. BMI, body mass index. ) p < 0.01: significant interaction between gender and BMI (p < 0.01).
the adipocyte induced systemic inflammation, which also has been recently confirmed. 21 The role of circulating leptin in the systemic manifestation of COPD has gained attention as leptin is linked to a pro-inflammatory state. 22 However until now, studies concerning circulating leptin concentration in clinically stable subjects with COPD found no significant differences in COPD and control subjects. 23 Possible reasons might be the limited number of patients included in these studies and the fact that only males and/or underweight patients were included. In the present study however, we showed a significant interaction between gender and BMI. Circulating leptin concentration was increased in overweight women with COPD, even after correction for fat mass. The cause for this phenomenon remains unclear. In the healthy population, it is well recognized that women have higher circulating leptin concentration compared to men. 24 Women have a higher fat mass percentage than men, resulting in higher circulating leptin secretion in women. Moreover, animal and in vitro studies confirmed that androgens have an inhibitory effect on circulating leptin secretion, whereas estradiol has a stimulatory effect. 25 Our study population consists of women with a median age of 59 years, implying that most women are post-menopausal, characterized by low estrogen levels. The changes in body composition occurring after the menopause (increase of body fat), induced by low estrogen concentrations, may lead to higher circulating leptin secretion. 26 It is therefore tempting to speculate that overweight COPD women suffer from an imbalance in sex hormones, which may explain the increased circulating plasma leptin levels in this COPD subgroup. Disturbances in the estrogen metabolism in women with COPD are not investigated yet, although estrogens are thought to be involved in the biological difference in susceptibility of the development of COPD. 27 No studies yet exist investigating the clinical outcomes of increased leptin concentrations in women with COPD. So, we can only speculate about possible consequences of an increased circulating leptin concentration, as the secretion of circulating leptin is an inter-player in the complex adipose secretory system. Nevertheless, there is evidence that leptin metabolism is linked to the inflammatory system, and in healthy, circulating leptin is more associated with plasma CRP concentration in women than in men. 12 In the present study, circulating leptin correlated with plasma CRP concentration in women with COPD, but not in men. Furthermore, the association of weight gain on systemic inflammation in subjects with COPD is higher in women than in men, 28 which is in line with the higher circulating leptin concentration in women with COPD that we found in our study. Moreover, circulating leptin was correlated with total glutathione concentration in elderly women, but neither in elderly men nor in younger peers. 24 Higher glutathione concentration in elderly women can favor systemic inflammation. As leptin is known to enhance the production of reactive oxygen species by leukocytes, 29 one could speculate that the increased leptin concentration in women with COPD is associated with increased oxidative stress. Herewith inline, Sin et al. recently proposed a mechanism by which women with COPD are more susceptible to COPD via a disbalance in the oxidant/ anti-oxidant pathway. 27 Whether the increased leptin concentration in women with COPD per se is associated with increased oxidative stress is not known yet, but COPD is generally characterized by a reduced anti-oxidant capacity and increased production of reactive oxygen species. 30 In healthy subjects, circulating leptin is a strong predictor for first-ever hemorrhagic stroke and myocardial infarction, 10, 11 suggesting that leptin is an important link in the development of cardiovascular disease. In post-menopausal women, circulating leptin is besides BMI a predictor for insulin resistance. 31 Whether women with COPD, particularly those who are overweight, suffer from more co-morbidities compared to their male counterparts is not known yet. As the lung is highly vascularized, the increased circulating levels of leptin may also contribute to the pathogenesis of lung inflammation and injury in COPD. Leptin is detectable in the pulmonary compartment 32, 33 of COPD patients, and leptin levels in induced sputum showed a positive correlation with those of CRP and TNFa. 32 In addition, we recently demonstrated that a functional leptin signaling pathway is present in both bronchial and alveolar epithelial cells, 33 indicating that leptin may be involved in the local inflammatory response in COPD. Further studies are warranted to investigate this hypothesis.
Plasma adiponectin, a protein largely secreted from adipose tissue, is known to increase fatty acid oxidation and reduce the synthesis of glucose in the liver. 34 Adiponectin has various protective anti-inflammatory effects on the metabolic derangements that may result in a lower risk for the development of atherosclerosis and type 2 diabetes. 35 Data about adiponectin concentration in patients with COPD are scarce and with inconclusive results. In the present study, circulating levels of adiponectin were higher in women compared to men, and tended to decrease with increasing BMI. These results are in consistence with previous reports concerning healthy subjects, 7 implying a physiological role of adiponectin in this cohort of COPD patients. Resistin is an adipocyte-derived protein that is positively associated with insulin resistance in rodents and humans. 36 Furthermore, it seems to induce, and also being induced by other pro-inflammatory cytokines, such as IL-6 and TNFa in humans. 34 To date, limited data are available on the exact role of resistin and the association of various pathological conditions, such as an increased insulin sensitivity, type 2 diabetes or factors related to the metabolic syndrome. 37 Data about levels of resistin in patients with COPD are limited, and in the present study, levels of plasma resistin concentration were not different between the COPD group and their healthy peers. The association between resistin and systemic inflammatory biomarkers found in the present study was also confirmed by others, 38 implying that resistin is also physiologically regulated in clinically stable patients with COPD.
Limitations of the study
One limitation of the study might be the small sample size, especially after stratifying the COPD patients into subgroups. However, other studies investigating plasma levels of adipokines in COPD patients have comparably small sample sizes 15, 16 and moreover, the results of our study showed statistical significant differences emphasizing considerable results. Another limitation is the lack of a direct outcome and possible consequences of increased levels of circulating leptin in COPD women. However, the present study is the first to show gender related differences in the adipose secretome system in COPD and further research will lead to a better understanding of the precise role of circulating leptin in COPD.
In conclusion, the results of the present study underscore gender related differences in the systemic biology of COPD. In men with clinically stable COPD, leptin, adiponectin and resistin appear to be physiologically regulated, while in women, leptin metabolism is likely altered. Leptin secretion is increased in women with COPD when compared to healthy women and compared to men with COPD, particularly in overweight women with COPD. Moreover, the present study confirms that subjects with COPD are characterized by low-grade systemic inflammation reflected in increased levels of CRP and IL-6.
